A new technique that allowed researchers to analyze genetic material from serum samples of HIV patients taken before AIDS was known provides a glimpse into the beginnings of the epidemic.
Researchers at the University of Arizona and the University of Cambridge in the U.K. have reconstructed the origins of the AIDS pandemic in unprecedented detail. (more…)
Researchers at Yale and Stanford have provided the most conclusive evidence to date that a rheumatoid arthritis drug can also be used to grow hair on patients with a disease that causes disfiguring hair loss. (more…)
In contrast, high doses appear not to work, UCLA study suggests
An estimated 3 million Americans suffer from epileptic seizures. Although drug therapies often successfully dampen the out-of-control neural firing that produces seizures, such drugs don’t work for everyone. (more…)
Research finds rapid brain ‘remapping’ in patients years after stroke
By examining the sense of touch in stroke patients, a University of Delaware cognitive psychologist has found evidence that the brains of these individuals may be highly plastic even years after being damaged.
The research is published in the March 6 edition of the journal Current Biology, in an article written by Jared Medina, assistant professor of psychology at UD, and Brenda Rapp of Johns Hopkins University’s Department of Cognitive Science. The findings, which are focused on patients who lost the sense of touch in their hands after a stroke, also have potential implications for other impairments caused by brain damage, Medina said. (more…)
Bedside Early-Warning System from IBM and Excel Medical Electronics Can Analyze Large Amounts of Data in Real Time to Predict Dangerous Changes in a Patient’s Condition
Armonk, N.Y. and Los Angeles, CA – 26 Mar 2013: IBM, and Excel Medical Electronics (EME) are collaborating with the UCLA Department of Neurosurgery in a study to test the effectiveness of a real-time alarm intended to predict rising brain pressure in patients with traumatic brain injuries. The experimental system uses big data analytics software developed by IBM Research and EME that analyzes in real-time streams of vital signs continuously collected from the bedside monitor to spot subtle changes in the patient’s pulse, blood and intracranial pressure, heart activity, and respiration, signaling that dangerous high-risk increases in brain pressure are on the way. (more…)
Antidepressants are the most widely used treatment for people with moderate to severe depression.
However, up to two thirds of people with depression don’t respond fully to this type of treatment. New findings have shown cognitive behavioural therapy (CBT), provided in addition to usual care, can reduce symptoms of depression and help improve patients’ quality of life.
This is the first large-scale trial to test the effectiveness of CBT – a type of talking psychotherapy- given in addition to usual care that includes antidepressants. The National Institute for Health Research Health Technology Assessment (NIHR HTA)-funded CoBalT study aimed to determine the best ‘next step’ treatment for people whose depression had not responded to medication alone. (more…)
EAST LANSING, Mich. — Often faced with overwhelming anxiety, patients newly diagnosed with lung cancer can find themselves in distress, and new research recommends nurses play a key role in alleviating concerns, leading to a better quality of life for patients.
A diagnosis of lung cancer – the leading cause of cancer death in the United States – brings with it high levels of stress and raises existential issues and death-related thoughts and concerns in patients, said Rebecca H. Lehto, assistant professor in the College of Nursing at Michigan State University. (more…)
Patients with metastatic melanoma taking the recently approved drug vemurafenib (marketed as Zelboraf) responded well to the twice-daily pill, but some of them developed a different, secondary skin cancer.
Now, researchers at UCLA’s Jonsson Comprehensive Cancer Center, working with investigators from the Institute of Cancer Research in London, Roche and Plexxikon, have elucidated the mechanism by which the drug excels at fighting melanoma but also allows for the development of skin squamous-cell carcinomas. (more…)
